Afficher la notice abrégée

dc.creatorDalrymple-Alford, J. C.en
dc.creatorMacAskill, M. R.en
dc.creatorNakas, C. T.en
dc.creatorLivingston, L.en
dc.creatorGraham, C.en
dc.creatorCrucian, G. P.en
dc.creatorMelzer, T. R.en
dc.creatorKirwan, J.en
dc.creatorKeenan, R.en
dc.creatorWells, S.en
dc.creatorPorter, R. J.en
dc.creatorWatts, R.en
dc.creatorAnderson, T. J.en
dc.date.accessioned2015-11-23T10:25:05Z
dc.date.available2015-11-23T10:25:05Z
dc.date.issued2010
dc.identifier10.1212/WNL.0b013e3181fc29c9
dc.identifier.issn0028-3878
dc.identifier.urihttp://hdl.handle.net/11615/26871
dc.description.abstractObjective: To establish the diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) when screening externally validated cognition in Parkinson disease (PD), by comparison with a PD-focused test (Scales for Outcomes in Parkinson disease-Cognition [SCOPA-COG]) and the standardized Mini-Mental State Examination (S-MMSE) as benchmarks. Methods: A convenience sample of 114 patients with idiopathic PD and 47 healthy controls was examined in a movement disorders center. The 21 patients with dementia (PD-D) were diagnosed using Movement Disorders Society criteria, externally validated by detailed independent functional and neuropsychological tests. The 21 patients with mild cognitive impairment (PD-MCI) scored 1.5 SD or more below normative data in at least 2 measures in 1 of 4 cognitive domains. Other patients had normal cognition (PD-N). Results: Primary outcomes using receiver operating characteristic (ROC) curve analyses showed that all 3 mental status tests produced excellent discrimination of PD-D from patients without dementia (area under the curve [AUC], 87%-91%) and PD-MCI from PD-N patients (AUC, 78%-90%), but the MoCA was generally better suited across both assessments. The optimal MoCA screening cutoffs were <21/30 for PD-D (sensitivity 81%; specificity 95%; negative predictive value [NPV] 92%) and <26/30 for PD-MCI (sensitivity 90%; specificity 75%; NPV 95%). Further support that the MoCA is at least equivalent to the SCOPA-COG, and superior to the S-MMSE, came from the simultaneous classification of the 3 PD patient groups (volumes under a 3-dimensional ROC surface, chance = 17%: MoCA 79%, confidence interval [CI] 70%-89%; SCOPA-COG 74%, CI 62%-86%; MMSE-Sevens item 56%, CI 44%-68%; MMSE-World item 62%, CI 50%-73%). Conclusions: The MoCA is a suitably accurate, brief test when screening all levels of cognition in PD. Neurology(R) 2010;75:1717-1725en
dc.sourceNeurologyen
dc.source.uri<Go to ISI>://WOS:000284473000012
dc.subjectNEUROPSYCHOLOGICAL CHARACTERISTICSen
dc.subjectRATING-SCALEen
dc.subjectDEMENTIAen
dc.subjectDISORDERen
dc.subjectINCIDENTen
dc.subjectDEFICITSen
dc.subjectMMSEen
dc.subjectTOOLen
dc.subjectClinical Neurologyen
dc.titleThe MoCA Well-suited screen for cognitive impairment in Parkinson diseaseen
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée